No Data
Express News | Nanjing Pharmaceutical: Approval granted for the issuance of ultra-short-term financing bonds.
Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s 2024 third quarter report
Full text of Nanjing Pharmaceutical\'s 2024 third quarter report
Express News | Nanjing Pharmaceutical: The net income attributable to the mother in the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.
Nanjing Pharmaceutical (600713.SH): The net income for the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.
Gelonghui October 30th | Nanjing Pharmaceutical (600713.SH) announced the third quarter report of 2024, with the company's revenue in the first three quarters of 40.938 billion yuan, a year-on-year increase of 0.97%; net income attributable to shareholders of the listed company was 0.442 billion yuan, a year-on-year increase of 0.36%; basic earnings per share was 0.34 yuan.
Nanjing Pharmaceutical (600713.SH): The application for issuing convertible bonds has been approved by the review committee of the Shanghai Stock Exchange.
Gelonghui October 16th | Nanjing Pharmaceutical (600713.SH) announced that the Shanghai Stock Exchange Listing Committee held the 24th review meeting of the year on October 16, 2024, to review the company's application to issue convertible corporate bonds to unspecified entities. According to the review results of the meeting, the company's application to issue convertible corporate bonds to unspecified entities complies with issuance conditions, listing conditions, and disclosure requirements.
No Data
No Data